Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Prenatal exposure to historical Ukraine Famine increases risk for Type 2 diabetes

Prenatal exposure to historical Ukraine Famine increases risk for Type 2 diabetes

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

ESC Congress to highlight results from global trials in six press conferences

ESC Congress to highlight results from global trials in six press conferences

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

Integrated treatment required for diabetes-eating disorder combination

Integrated treatment required for diabetes-eating disorder combination

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

IOF, EOS to jointly hold Middle East & Africa Osteoporosis Meeting in Abu Dhabi

IOF, EOS to jointly hold Middle East & Africa Osteoporosis Meeting in Abu Dhabi

EUMODIC brings together scientists to study functions of 320 genes in mice

EUMODIC brings together scientists to study functions of 320 genes in mice

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Regular exercise, healthy diet may help reduce knee pain for overweight adults with diabetes

Regular exercise, healthy diet may help reduce knee pain for overweight adults with diabetes

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Resverlogix and Hepalink close license agreement, sign definitive stock purchase agreement

Resverlogix and Hepalink close license agreement, sign definitive stock purchase agreement

Modified, healthier meal plan for youth with type 1 diabetes more expensive

Modified, healthier meal plan for youth with type 1 diabetes more expensive

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.